

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

NCT05866302

Status RECRUITING
Sponsor University of Michigan Rogel Cancer Center
Enrollment 375 participants

Key Eligibility Criteria

Inclusion (7)

- For both Cohorts 1 and 2:
- Age ≤ 36 months. There is no upper age limit.
- Receipt of an allogeneic HCT. There are no exclusions to study entry based upon primary diagnosis, hematopoietic cell source, conditioning regimen, donor type, degree of donor-recipient HLA match, or current organ function.
- All patients and/or their parents or legal guardians must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
- Cohort 1 (Chronic Graft Versus Host Disease): Diagnosis of chronic GVHD in at least 1 organ system within the prior 3 months. NIH Consensus Criteria for chronic GVHD are required to establish the diagnosis. (<https://pubmed.ncbi.nlm.nih.gov/25529383/>)
- ... and 2 more (see full listing online)

Exclusion (3)

- Relapse of a patient's primary malignancy post-HCT, or the development of any secondary "hematologic" malignancy post-HCT.
- The presence of an active, uncontrolled infection.
- Patients who would require intubation solely for the purposes of obtaining a CT scan for PRM imaging. (In contrast, if a clinical CT is being performed as routine medical care to evaluate a patient's lung function, the patient is eligible and PRM imaging may be performed from that CT.)

Locations (6 total)

Stanford Hospital, Stanford, California, United States
Emory University, Atlanta, Georgia, United States
Dana Farber, Boston, Massachusetts, United States
... and 3 more locations